Drug-drug interactions involving the membrane transport process

Drug-Drug Interactions

Volumn , Issue , 2001, Pages 123-188

  Kusuhara, Hiroyuki ^a,b   Sugiyama, Yuichi ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 14044261480     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (309)

1. T Komai, K Kawai, T Tokui, Y Tokui, C Kuroiwa, E Shigehara, M Tanaka. Disposition and metabolism of pravastatin sodium in rats, dogs and monkeys. Eur J Drug Metab Pharmacokinet 17: 103-113, 1992.
2. M Ishigami, T Tokui, T Komai, K Tsukahara, M Yamazaki, Y Sugiyama. Evaluation of the uptake of pravastatin by perfused rat liver and primary cultured rat hepatocytes. Pharm Res 12: 1741-1745, 1995.
3. I Tarnai, H Takanaga, H Maeda, T Ogihara, M Yoneda, A Tsuji. Proton-cotransport of pravastatin across intestinal brush-border membrane. Pharm Res 12: 1727-1732, 1995.
4. M Yamazaki, S Akiyama, K Ni’inuma, R Nishigaki, Y Sugiyama. Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter. Drug Metab Dispos 25: 1123-1129, 1997.
5. M Yamazaki, H Suzuki, M Hanano, T Tokui, T Komai, Y Sugiyama. Na(+)-independent multispecific anion transporter mediates active transport of pravastatin into rat liver. Am J Physiol 264: G36-44, 1993.
6. K Ito, T Iwatsubo, S Kanarnitsu, K Veda, H Suzuki, Y Sugiyama. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 50: 387-412, 1998.
7. K Veda, Y Kato, K Komatsu, Y Sugiyama. Inhibition of biliary excretion of methotrexate by probenecid in rats: Quantitative prediction of interaction from in vitro data. J Pharmacol Exp Ther (in press).
8. K Ito, T Iwatsubo, S Kanamitsu, Y Nakajima, Y Sugiyama. Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Annu Rev Pharmacol Toxicol 38: 461-499, 1998.
9. T Wilson, G Wiselman. The use of sacs of everted small intestine for the study of the transference of substances from the mucosal to serosal surface. J Physiol 123: 116-125, 1954.
10. WH Barr, S Riegelman. Intestinal drug absorption and metabolism. II. Kinetic aspects of intestinal glucoronide conjugation. J Pharm Sci 59: 164-168, 1970.
11. RA Frizzell, MJ Koch, SG Schultz. Ion transport by rabbit colon. I. Active and passive components. J Membr Biol 27: 297-316, 1976.
12. RA Frizzell, SA Schultz. Ionic conductances of extracellular shunt pathway in rabbit ileum. Influence of shunt on transmural sodium transport and electrical potential differences. J Gen Physiol 59: 318-346, 1972.
13. R Kannan, A Mittur, Y Bao, T Tsuruo, N Kaplowitz. GSH transport in immortalized mouse brain endothelial cells: evidence for apical localization of a sodiumdependent GSH transporter. J Neurochem 73: 390-399, 1999.
14. H Kusuhara, H Suzuki, M Naito, T Tsuruo, Y Sugiyama. Characterization of efflux transport of organic anions in a mouse brain capillary endothelial cell line. J Pharmacol Exp Ther 285: 1260-1265, 1998.
15. JB Pritchard, DS Miller. Mechanisms mediating renal secretion of organic anions and cations. Physiol Rev 73: 765-796, 1993.
16. MM Sanchez del Pino, RA Hawkins, DR Peterson. Neutral amino acid transport by the blood-brain barrier. Membrane vesicle studies. J Biol Chem 267: 25951-25957, 1992.
17. H Murer, P Gmaj, B Steiger, B Hagenbuch. Transport studies with renal proximal tubular and small intestinal brush border and basolateral membrane vesicles: vesicle heterogeneity, coexistence of transport system. Methods Enzymol 172: 346-364, 1989.
18. JL Boyer, PJ Meier. Characterizing mechanisms of hepatic bile acid transport utilizing isolated membrane vesicles. Methods Enzymol 192: 517-533, 1990.
19. E Kinne-Saffran, RK Kinne. Isolation oflumenal and contralumenal plasma membrane vesicles from kidney. Methods Enzymol 191: 450-469, 1990.
20. PJ Meier, JL Boyer. Preparation of basolateral (sinusoidal) and canalicular plasma membrane vesicles for the study of hepatic transport processes. Methods Enzymol 192: 534-545, 1990.
21. PJ Meier, A S1. Meier-Abt, C Barrett, JL Boyer. Mechanisms of taurocholate transport in canalicular and basolateral rat liver plasma membrane vesicles. Evidence for an electrogenic canalicular organic anion carrier. J Biol Chem 259: 10614-10622, 1984.
22. Y Kamimoto, Z Gatmaitan, J Hsu, JM Arias. The function of Gp170, the multidrug resistance gene product, in rat liver canalicular membrane vesicles. J Biol Chem 264: 11693-11698, 1989.
23. AH Dantzig, L Bergin. Uptake of the cephalosporin, cephalexin, by a dipeptide transport carrier in the human intestinal cell line, Caco-2. Biochim Biophys Acta 1027: 211-217, 1990.
24. G Wilson. Cell culture techniques for the study of drug transport. Eur J Drug Metab Pharmacokinet 15: 159-163, 1990.
25. L Barthe, J Woodley, G Houin. Gastrointestinal absorption of drugs: methods and studies. Fundam Clin Pharmacol 13: 154-168, 1999.
26. R Kekuda, V Torres-Zamorano, YJ Fei, PD Prasad, HW Li, LD Mader, FH Leibach, V Ganapathy. Molecular and functional characterization of intestinal Na(+)-dependent neutral amino acid transporter BO. Am J Physiol 272: Gl463-1472, 1997.
27. I Tarnai, H Takanaga, H Maeda, Y Sai, T Ogihara, H Higashida, A Tsuji. Participation of a proton-cotransporter, MCT1, in the intestinal transport of monocarboxylic acids. Biochem Biophys Res Commun 214: 482-489, 1995.
28. SK Basu, J Shen, KJ Elbert, CT Okamoto, VH Lee, H von Grafenstein. Develop- ment and utility of anti-PepTl anti-peptide polyclonal antibodies. Phann Res 15: 338-342, 1998.
29. J Hunter, MA Jepson, T Tsuruo, NL Simmons, BH Hirst. Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators. J Biol Chem 268: 14991-14997, 1993.
30. V Meunier, M Bourrie, Y Berger, G Fabre. The human intestinal epithelial cell line Caco-2: phannacological and phannacokinetic applications. Cell Biol Toxicol 11: 187-194, 1995.
31. MC Gres, B Julian, M Bourrie, V Meunier, C Roques, M Berger, X Boulenc, Y Berger, G Fabre. Correlation between oral drug absorption in humans, and apparent drug penneability in TC-7 cells, a human epithelial intestinal cell line: comparison with the parental Caco-2 cell line. Phann Res 15: 726-733, 1998.
32. J Hunter, BH Hirst, NL Simmons. Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cell layer. Phann Res 10: 743-749, 1993.
33. A Baranczyk-Kuzma, JA Garren, IJ Hidalgo, RT Borchardt. Substrate specificity and some properties of phenol sulfotransferase from human intestinal Caco-2 cells. Life Sci 49: 1197-1206, 1991.
34. I Chantret, A Barbat, E Dussaulx, MG Brattain, A Zweibaum. Epithelial polarity, villin expression, and enterocytic differentiation of cultured human colon carcinoma cells: a survey of twenty cell lines. Cancer Res 48: 1936-1942, 1988.
35. X Boulenc, M Bourrie, I Fabre, C Roque, H Joyeux, Y Berger, G Fabre. Regulation of cytochrome P450IAI gene expression in a human intestinal cell line, Caco-2. J Phannacol Exp Ther 263: 1471-1478, 1992.
36. VJ Wacher, JA Silvennan, Y Zhang, LZ Benet. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Phann Sci 87: 1322-1330, 1998.
37. P Schmiedlin-Ren, KE Thummel, JM Fisher, MF Paine, KS Lown, PB Watkins. Expression ofenzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated penneable supports in the presence of 1 alpha, 25-dihydroxyvitarnin D3. Mol Phannacol 51: 741-754, 1997.
38. CL Crespi, BW Penman, M Hu. Development of Caco-2 cells expressing high levels of cDNA-derived cytochrome P4503A4. Phann Res 13: 1635-1641, 1996.
39. M Hu, Y Li, CM Davitt, SM Huang, K Thummel, BW Penman, CL Crespi. Transport and metabolic characterization of Caco-2 cells expressing CYP3A4 and CYP3A4 plus oxidoreductase. Pharm Res 16: 1352-1359, 1999.
40. VJ Wacher, CY Wu, LZ Benet. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13: 129-134, 1995.
41. K Ito, H Kusuhara, Y Sugiyama. Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption-theoretical approach. Phann Res 16: 225-231, 1999.
42. D Grundemann, J Babin-Ebell, F Martel, N Ording, A Schmidt, E Schomig. Primary structure and functional expression of the apical organic cation transporter from kidney epithelial LLC-PKI cells. J Biol Chem 272: 10408-10413, 1997.
43. R Hori, M Okamura, A Takayama, K Hirozane, M Takano. Transport of organic anion in the OK kidney epithelial cell line. Am J Physiol 264: F975-980, 1993.
44. G Yuan, RJ Ott, C Salgado, KM Giacomini. Transport of organic cations by a renal epithelial cell line (OK). J Biol Chem 266: 8978-8986, 1991.
45. M Takano, K Hirozane, M Okamura, A Takayama, J Nagai, R Hori. p-Arninohippurate transport in apical and basolateral membranes of the OK kidney epithelial cells. J Pharmacol Exp Ther 269: 970-975, 1994.
46. J Nagai, I Yano, Y Hashimoto, M Takano, K Inui. Efflux of intracellular alphaketoglutarate via p-aminohippurate/dicarboxylate exchange in OK kidney epithelial cells. J Pharmacol Exp Ther 285: 422-427, 1998.
47. T Tatsuta, M Naito, T Oh-hara, I Sugawara, T Tsuruo. Functional involvement of P-glycoprotein in blood-brain barrier. J Biol Chem 267: 20383-20391, 1992.
48. KI Hosoya, T Terasaki, K Tetsuka, T Nagura, S Ontsuki, H Takanaga, M Veda, N Yanai, M Obitani, T Terasaki. mRNA expression and transport characterization of conditionally immortalized rat brain capillary endothelial cell lines: A new in vitro bbb model for drug targeting. J Drug Target 8: 357-370, 2000.
49. DJ Begley, D Lechardeur, ZD Chen, C Rollinson, MBardoul, F Roux, D Scherman, NJ Abbott. Functional expression of P-glycoprotein in an immortalized cell line of rat brain endothelial cells, RBE4. J Neurochem 67: 988-995, 1996.
50. MA Barrand, KJ Robertson, SF von Weikersthal. Comparisons of P-glycoprotein expression in isolated rat brain microvessels and in primary cultures of endothelial cells derived from microvasculature of rat brain, epididymal fat pad and from aorta. FEBS Lett 374: 179-183, 1995.
51. S Seetharaman, MA Barrand, L Maskell, RJ Scheper. Multidrug resistance-related transport proteins in isolated human brain microvessels and in cells cultured from these isolates. J Neurochem 70: 1151-1159, 1998.
52. A Regina, A Koman, M Piciotti, B El Hafny, MS Center, R Bergmann, PO Couraud, F Roux. Mrpl multidrug resistance-associated protein and P-glycoprotein expression in rat brain microvessel endothelial cells. J Neurochem 71: 705-715, 1998.
53. Y Kato, S Akhteruzzaman, A Hisaka, Y Sugiyama. Hepatobiliary transport governs overall elimination of peptidic endothelin antagonists in rats. J Pharmacol Exp Ther 288: 568-574, 1999.
54. AP Li, P Maurel, MJ Gomez-Lechon, LC Cheng, M Jurima-Romet. Preclinical evaluation of drug-drug interaction potential: present status of the application of primary human hepatocytes in the evaluation of cytochrome P450 induction. Chem Biol Interact 107: 5-16, 1997.
55. AP Li, PD Gorycki, JG Hengstler, GL Kedderis, HG Koebe, R Rahmani, G de Sousas, JM Silva, P Skett. Present status of the application ofcryopreserved hepatocytes in the evaluation of xenobiotics: consensus of an international expert panel. Chem Biol Interact 121: 117-123, 1999.
56. AP Li, C Lu, JA Brent, C Pham, A Fackett, CE Ruegg, PM Silber. Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential. Chem Biol Interact 121: 17-35, 1999.
57. EL LeCluyse, KL Audus, JH Hochman. Formation of extensive canalicular net- works by rat hepatocytes cultured in collagen-sandwich configuration. Am J Physiol 266: C1764-1774, 1994.
58. X Liu, JP Chism, EL LeCluyse, KR Brouwer, KL Brouwer. Correlation of biliary excretion in sandwich-cultured rat hepatocytes and in vivo in rats. Drug Metab Dispos 27: 637-644, 1999.
59. 2+ modulation to evaluate biliary excretion in sandwich-cultured rat hepatocytes. J Pharmacol Exp Ther 289: 1592-1599, 1999.
60. AH Schinkel, U Mayer, E Wagenaar, CAAM Mol, L van Deemter, 1JM Smit, MA van der Valk, AC Voordouw, HSpits, O van Tellingen, JMJM Zijlmans, WE Fibbe, P Borst. Normal viability and altered pharmacokinetics in mice lacking mdrl-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 94: 4028-4033, 1997.
61. J Wijnholds, REvers, MR van Leusden, CA Mol, GJ Zaman, U Mayer, JH Beijnen, M van der Valk, P Krimpenfort, P Borst. Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. Nat Med 3: 1275-1279, 1997.
62. F Kuipers, M Enserink, R Havinga, AB van der Steen, MJ Hardonk, J Fevery, RJ Vonk. Separate transport systems for biliary secretion of sulfated and unsulfated bile acids in the rat. J Clin Invest 81: 1593-1599, 1988.
63. PL Jansen, WH Peters, WH Lamers. Hereditary chronic conjugated hyperbilirubinemia in mutant rats caused by defective hepatic anion transport. Hepatology 5: 573-579, 1985.
64. S Hosokawa, O Tagaya, T Mikami, Y Nozaki, A Kawaguchi, K Yamatsu, M Shamoto. A new rat mutant with chronic conjugated hyperbilirubinemia and renal glomerular lesions. Lab Animal Sci 42: 27-34, 1992.
65. B Hagenbuch, BF Scharschmidt, PJ Meier. Effect of antisense oligonucleotides on the expression of hepatocellular bile acid and organic anion uptake systems in Xenopus laevis oocytes. Biochem J 316: 901-904, 1996.
66. I Tarnai, T Nakanishi, K Hayashi, T Terao, Y Sai, T Shiraga, K Miyamoto, E Takeda, H Higashida, A Tsuji. The predominant contribution of oligopeptide transporter PepTl to intestinal absorption of beta-Iactam antibiotics in the rat small intestine. J Pharm Pharmacol 49: 796-801, 1997.
67. H Kouzuki, H Suzuki, K Ito, R Ohashi, Y Sugiyama. Contribution of sodium taurocholate co-transporting polypeptide to the uptake of its possible substrates into rat hepatocytes. J Pharmacol Exp Ther 286: 1043-1050, 1998.
68. H Kouzuki, H Suzuki, K Ito, R Ohashi, Y Sugiyama. Contribution of organic anion transporting polypeptide to uptake of its possible substrates into rat hepatocytes. J Pharmacol Exp Ther 288: 627-634, 1999.
69. V Gorboulev, JC Ulzheimer, A Akhoundova, I Ulzheimer-Teuber, U Karbach, S Quester, C Baumann, F Lang, AE Busch, H Koepsell. Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol 16: 871-881, 1997.
70. D Grundemann, V Gorboulev, S Gambaryan, M Veyhl, H Koepsell. Drug excretion mediated by a new prototype of polyspecific transporter. Nature 372: 549-552, 1994.
71. F Meyer-Wentrup, U Karback, V Gorvoulev, P Arndt, H Koepsell. Membrane 10- calization of the electrogenic cation transporter roctl in rat liver. Biochem Biophys Res Commun 248: 673-678, 1998.
72. Y Urakami, M Okuda, S Masuda, H Saito, K Inui. Functional characteristics and membrane localization of rat multispecific organic cation transporters, octl and oct2, mediating tumular secretion of cationic drugs. J Pharmacol Exp Ther 287: 800-805, 1998.
73. H Koepsell. Organic cation transporters in intestine, kidney, liver, and brain. Annu Rev Physiol 60: 243-266, 1998.
74. AE Busch, S Quester, JC Ulzheimer, S Waldegger, V Gorboulev, P Arndt, F Lang, H Koepsell. Electrogenic properties and substrate specificity of the polyspecific rat cation transporter rOCTI. J Biol Chem 271: 32599-32604, 1996.
75. G Nagel, C Yolk, T Friedrich, JC Ulzheimer, E Bamberg, H Koepsell. A reevaluation of substrate specificity of the rat cation transporter rOCTI. J Biol Chem 272: 31953-31956, 1997.
76. R Kekuda, PD Prasad, X Wu, HWang, YJ Fei, FH Leibach, V Ganapathy. Cloning and functional characterization of a potential-sensitive, polyspecific organic cation transporter (OCT3) most abundantly expressed in placenta. J Biol Chem 273: 15971-15979, 1998.
77. D Grundemann, G Liebich, N Kiefer, S Koster, E Schomig. Selective substrates for non-neuronal monoamine transporters. Mol Pharmacol 56: 1-10, 1999.
78. E Jacquemin, B Hagenbuch, B Stieger, AWWolkoff, PJ Meier. Expression cloning of a rat liver Na(+)-independent organic anion transporter. Proc Natl Acad Sci USA 91: 133-137, 1994.
79. AJ Bergwerk, X Shi, AC Ford, N Kanai, E Jacquemin, RD Burk, S Bai, PM Novikoff, B Stieger, PJ Meier, VL Schuster, AW Wolkoff. Immunologic distribution of an organic anion transport protein in rat liver and kidney. Am J Physiol 271: G231-238, 1996.
80. RH Angeletti, PM Novikoff, SR Juvvadi, JM Fritschy, PJ Meier, AW Wolkoff. The choroid plexus epithelium is the site of the organic anion transport protein in the brain. Proc Natl Acad Sci USA 94: 283-286, 1997.
81. JE van Montfoort, B Hagenbuch, KE Fattinger, MI M, GM Groothuis, DK Meijer, PJ Meier. Polyspecific organic anion transporting polypeptides mediate hepatic uptake of amphipathic type II organic cations. J Pharmacol Exp Ther 291: 147-152, 1999.
82. M Muller, PL Jansen. Molecular aspects of hepatobiliary transport. Am J Physiol 272: G1285-1303, 1997.
83. PJ Meier, U Eckhardt, A Schroeder, B Hagenbuch, B Stieger. Substrate specificity of sinusoidal bile acid and organic anion uptake systems in rat and human liver. Hepatol 26: 1667-1677, 1997.
84. L Li, TK Lee, PJ Meier, N Ballatori. Identification of glutathione as a driving force and leukotriene C4 as a substrate for oatpl, the hepatic sinusoidal organic solute transporter: J Biol Chem 273: 16184-16191, 1998.
85. M Kakyo, H Sakagami, T Nishio, D Nakai, R Nakagomi, T Tokui, T Naitoh, S Matsuno, T Abe, H Yawo. Immunohistochemical distribution and functional characterization of an organic anion transporting polypeptide 2 (oatp2). FEBS Lett 445: 343-346, 1999.
86. C Reichel, B Gao, J Van Montfoort, V Cattori, C Rahner, B Hagenbuch, B Stieger, T Kamisako, PJ Meier. Localization and function of the organic anion-transporting polypeptide oatp2 in rat liver. Gastroenterol 117: 688-695, 1999.
87. B Noe, B Hagenbuch, B Stieger, PJ Meier. Isolation of a multispecific organic anion and cardiac glycoside transporter from rat brain. Proc Nail Acad Sci USA 94: 10346-10350, 1997.
88. T Abe, M Kakyo, H Sakagami, T Tokui, T Nishio, M Tanemoto, H Nomura, SC Hebert, S Matsuno, H Kondo, H Yawo. Molecular characterization and tissue distribution of a new organic anion transporter subtype (oatp3) that transports thyroid hormones and taurocholate and comparison with oatp2. J Biol Chem 273: 22395-22401, 1998.
89. S Masuda, K Ibaramoto, A Takeuchi, H Saito, Y Hashimoto, KI Inui. Cloning and functional characterization of a new multispecific organic anion transporter, OATK2, in rat kidney. Mol Pharmacol 55: 743-752, 1999.
90. H Saito, S Masuda, K Inui. Cloning and functional characterization of a novel rat organic anion transporter mediating basolateral uptake of methotrexate in the kidney. J Biol Chem 271: 20719-20725, 1996.
91. B Gao, B Stieger, B No, JM Fritschy, PJ Meier. Localization of the organic anion transporting polypeptide 2 (oatp2) in capillary endothelium and choroid plexus epithelium of rat brain. J Histochem Cytochem 47: 1255-1264, 1999.
92. WA Banks, AJ Kastin. Passage of peptides across the blood-brain barrier: pathopysiological perspectives. Life Sci 59: 1923-1943, 1996.
93. S Masuda, H Saito, H Nonoguchi, K Tomita, K Inui. mRNA distribution and membrane localization of the OAT-Kl organic anion transporter in rat renal tubules. FEBS Lett 407: 127-131, 1997.
94. GA Kullak-Ublick, B Hagenbuch, B Stieger, CO Schteingart, AF Hofmann, AW Wolkoff, PJ Meier. Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology 109: 1274-1282, 1995.
95. X Bossuyt, M Muller, PJ Meier. Multispecific amphipathic substrate transport by an organic anion transporter of human liver. J Hepatol 25: 733-738, 1996.
96. T Abe, M Kakyo, T Tokui, R Nakagomi, T Nishio, D Nakai, H Nomura, M Unno, M Suzuki, T Naitoh, S Matsuno, H Yawo. Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem 274: 17159-17163, 1999.
97. J Konig, Y Cui, AT Nies, O Keppler. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol 278: G0156-G164, 2000.
98. B Hsiang, Y Zhu, Z Wang, Y Wu, V Sasseville, WP Yang, TG Kirchgessner. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 274: 37161-37168, 1999.
99. M Kakyo, M Unno, T Tokui, R Nakagomi, T Nishio, H Iwasashi, D Nakai, M Seki, M Suzuki, T Naitoh, S Matsuno, H Yawo, T Abe. Molecular characterization and functional regulation of a novel rat liver-specific organic anion transporter rlst1. Gastroenterology 117: 770-775, 1999.
100. T Nagase, K Ishikawa, N Miyajima, A Tanaka, H Kotani, N Nomura, D Ohara. Prediction of the coding sequences of unidentified human genes. IX. The complete sequences of 100 new eDNA clones from brain which can code for large proteins in vitro. DNA Res 5: 31-39, 1998.
101. JV Moller, MI Sheikh. Renal organic anion transport system: pharmacological, physiological, and biochemical aspects. Pharmacol Rev 34: 315-358, 1983.
102. KJ Ullrich, G Rumrich. Renal transport mechanisms for xenobiotics: chemicals and drugs. Clin Invest 71: 843-848, 1993.
103. S Jariyawat, T Sekine, M Takeda, N Apiwattanakul, Y Kanai, S Sophasan, H Endou. The interaction and transport of beta-Iactam antibiotics with the cloned rat renal organic anion transporter 1. J Pharmacol Exp Ther 290: 672-677, 1999.
104. N Apiwattanakul, T Sekine, A Chairoungdua, Y Kanai, N Nakajima, S Sophasan, H Endou. Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol Pharmacol 55: 847-854, 1999.
105. M Tsuda, T Sekine, M Takeda, SH Cha, Y Kanai, M Kimura, H Endou. Transport of ochratoxin A by renal multispecific organic anion transporter 1. J Pharmacol Exp Ther 289: 1301-1305, 1999.
106. T Sekine, N Watanabe, M Hosoyamada, Y Kanai, H Endou. Expression cloning and characterization of a novel multispecific organic anion transporter. J Biol Chem 272: 18526-18529, 1997.
107. DH Sweet, NA Wolff, JB Pritchard. Expression cloning and characterization of ROATI. The basolatal organic anion transporter in rat kidney. J Biol Chem 272: 30088-30095, 1997.
108. A Tojo, T Sekine, N Nakajima, M Hosoyamada, Y Kanai, K Kimura, H Endou. Immunohistochemical localization of multispecific renal organic anion transporter 1 in rat kidney. J Am Soc Nephrol 10: 464-471, 1999.
109. H Kusuhara, T Sekine, N Utsunomiya-Tate, M Tsuda, R Kojima, SH Cha, Y Sugiyama, Y Kanai, H Endou. Molecular cloning and characterization of a new multispecific organic anion transporterfrom rat brain. J Biol Chem 274: 13675-13680, 1999.
110. T Sekine, SH Cha, M Tsuda, N Apiwattanakul, N Nakajima, Y Kanai, H Endou. Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett 429: 179-182, 1998.
111. SH Cha, T Sekine, H Kusuhara, E Yu, JY Kim, DK Kim, Y Sugiyama, Y Kanai, H Endou. Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. J Biol Chem 275: 4507-4512, 2000.
112. JE Race, SM Grassl, WJ Williams, EJ Holtzman. Molecular cloning and characterization of two novel human renal organic anion transporters (hOAT1 and hOAT3). Biochem Biophys Res Commun 255: 508-514, 1999.
113. KJ Ullrich, G Rumrich, C David, G Fritzsch. Bisubstrates: substances that interact with renal contraluminal organic anion and organic cation transport systems. I. Amines, piperidines, piperazines, azepines, pyridines, quinolines, imidazoles, thiazoles, guanidines and hydrazines. Pflugers Arch 425: 280-299, 1993.
114. I Tarnai, H Yabuuchi, J Nezu, Y Sai, A Oku, M Shimane, A Tsuji. Cloning and characterization of a novel human pH-dependent organic cation transporter, OCTNI. FEBS Lett 419: 107-111, 1997.
115. H Yabuuchi I Tarnai, J Nezu, K Sakamoto, A Oku, M Shimane, Y Sai, A Tsuji. Novel membrane transporter OCTNI mediates multispecific, bidirectional, and pHdependent transport of organic cations. J Pharmacol Exp Ther 289: 768-773, 1999.
116. X Wu, PD Prasad, FH Leibach, V Ganapathy. cDNA sequence, transport function, and genomic organization of human OCTN2, a new member of the organic cation transporter family. Biochem Biophys Res Commun 246: 589-595, 1998.
117. I Tarnai, R Ohashi, J Nezu, H Yabuuchi, A Oku, M Shimane, Y Sai, A Tsuji. Molecular and functional identification of sodium ion-dependent, high affinity human camitine transporter OCTN2. J Biol Chem 273: 20378-20382, 1998.
118. J Kerner, C Hoppel. Genetic disorders of camitine metabolism and their nutritional management. Annu Rev Nutr 18: 179-206, 1998.
119. V Tanphaichitr, P Leelahagul. Camitine metabolism and human camitine deficiency. Nutrition 9: 246-254, 1993.
120. J Nezu, I Tarnai, A Oku, R Ohashi, H Yabuuchi, N Hashimoto, H Nikaido, Y Sai, A Koizumi, Y Shoji, G Takada, T Matsuishi, M Yoshino, H Kato, T Ohura, G Tsujimoto, J Hayakawa, M Shimane, A Tsuji. Primary systemic camitine deficiency is caused by mutations in a gene encoding sodium ion-dependent camitine transporter. Nat Genet 21: 91-94, 1999.
121. X Wu, W Huang, PD Prasad, P Seth, DP Rajan, FH Leibach, J Chen, SJ Conway, V Ganapathy. Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter. J Pharmacol Exp Ther 290: 1482-1492, 1999.
122. R Ohashi, I Tarnai, H Yabuuchi, JI Nezu, A Oku, Y Sai, M Shimane, A Tsuji, Na(+)-dependent camitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther 291 : 778-784, 1999.
123. ME Ganapathy, W Huang, DP Rajan, AL Carter, M Sugawara, K Iseki, FH Leibach, V Ganapathy. Beta-Iactam antibiotics as substrates for OCTN2, an organic cation/camitine transporter. J Biol Chem 275: 1699-1707, 2000.
124. YJ Fei, Y Kanai, S Nussberger, V Ganapathy, FH Leibach, MF Romero, SK Singh, WF Boron, MA Hediger. Expression cloning of a mammalian proton-coupled oligopeptide transporter. Nature 368: 563-566, 1994.
125. H Ogihara, H Saito, BC Shin, T Terado, S Takenoshita, Y Nagamachi, K Inui, K Takata. Immuno-Iocalization of H+Ipeptide cotransporter in rat digestive tract. Biochem Biophys Res Commun 220: 848-852, 1996.
126. H Shen, DE Smith, T Yang, YG Huang, JB Schnermann, FC Brosius. 3rd Localization ofPEPTI and PEPT2 proton-coupled oligopeptide transporter mRNA and protein in rat kidney. Am J Physiol 276: F658-655, 1999.
127. A Steel, S Nussberger, MF Romero, WF Boron, CA Boyd, MA Hediger. Stoichiometry and pH dependence of the rabbit proton-dependent oligopeptide transporter PepTl. J Physiol 498: 563-569, 1997.
128. F Doring, J Will, S Amasheh, W Clauss, H Ahlbrecht, H Daniel. Minimal molecular determinants of substrates for recognition by the intestinal peptide transporter. J Biol Chem 273: 23211-23218, 1998.
129. SWeller, MR Blum, M Doucette, T Burnette, DM Cederberg, P de Miranda, ML Smiley. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther 54: 595-605, 1993.
130. PJ Shinko, PV Sinko, PV Balimane. Carrier-mediated intestinal absorption of valacyclovir, the L-valyl ester prodrug of acyclovir: l. Interactions with peptides, organic anions and organic cations in rats. Biopharm Drug Dispos 19: 209-217, 1998.
131. J Soul-Lawton, E Seaber, NOn, R Wootton, PRolan, J Posner. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrob Agents Chemother 39: 2759-2764, 1995.
132. ME Ganapathy, W Huang, H Wang, V Ganapathy, FH Leibach. Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPTI and PEPTI. Biochern Biophys Res Commun 246: 470-475, 1998.
133. H Han, RL de Vrueh, JK Rhie, KM Covitz, PL Smith, CP Lee, DM Oh, W Sadee, GL Amidon. 5'-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPTI peptide transporter. Pharm Res 15: 1154-1159, 1998.
134. I Tarnai, T Nakanishi, H Nakahara, Y Sai, V Ganapathy, FH Leibach, A Tsuji. Improvement of L-dopa absorption by dipeptidyl derivation, utilizing peptide transporter PepTl. J Pharm Sci 87: 1542-1546, 1998.
135. H Saito, T Terada, M Okuda, S Sasaki, K Inu L Molecular cloning and tissue distribution of rat peptide transporter PEPT2. Biochim Biophys Acta 1280: 173-177, 1996.
136. M BoH, M Herget, M Wagener, WM Weber, D Markovich, J Biber, W Clauss, H Murer, H Daniel. Expression cloning and functional characterization of the kidney cortex high-affinity proton-coupled peptide transporter. Proc Natl Acad Sci USA 93: 284-289, 1996.
137. DE Smith, A Pavlova, UV Berger, MA Hediger, T Yang, YG Huan, JB Schnermann. Tubular localization and tissue distribution of peptide transporters in rat kidney. Pharm Res 15: 1244-1249, 1998.
138. ST Dieck, H Heuer, J Ehrchen, COtto, K Bauer. The peptide transporter PepTI is expressed in rat brain and mediates the accumulation of the florescent dipeptide derivative. Glia 25: 10-20, 1998.
139. XZ Chen, T Zhu, DE Smith, MA Hediger. Stoichiometry and kinetics of the highaffinity H+-coupled peptide transporter PepTI. J Biol Chem 274: 2773-2779, 1999.
140. T Terada, H Saito, M Mukai, K Inui. Recognition of beta-Iactam antibiotics by rat peptide transporter, PEPTl and PEPT2, in LLC-PKI cells. Am J Physiol 273: F706-F711, 1997.
141. S Ramamoorthy, W Liu, YY Ma, TL Yang-Feng, V Ganapathy, FH Leibach, Proton/peptide cotransporter (pEPT 2) from human kidney: functional characterization and chromosomal localization. Biochim Biophys Acta 1240: 1-4, 1995.
142. K Takahasi, N Nakamura, T Terada, T Okano, T Futami, H Saito, K Inu L Interaction of beta-Iactam antibiotics with H+ peptide cotransporters in rat renal brush border membranes. J Pharmcol Exp Ther 286: 1037-1042, 1998.
143. AE Busch, A Schuster, S Waldegger, CA Wagner, G Zempel, S Broer, J Biber, H Murer, F Lang. Expression of a renal type I sodium/phosphate transporter (NaPi1) induces a conductance in Xenopus oocytes permeable for organic and inorganic anions. Proc Natl Acad Sci USA 93: 5347-5351, 1996.
144. H Yabuuchi, I Tarnai, K Morita, T Kouda, K Miyamoto, E Takeda, A Tsuji. Hepatic sinusoidal membrane transport of anionic drugs mediated by anion transporter Nptl. J Pharmacol Exp Ther 286: 1391-1396, 1998.
145. K Dano. Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochim Biophys Acta 323: 466-483, 1973.
146. T Skovsgaard. Mechanisms of resistance to daunorubicin in Ehrlich ascites tumor cells. Cancer Res 38: 1785-1791, 1978.
147. RPJ Oude Elferink, DKF Meijer, F Kuipers, PLM Jansen, AK Groen, GMM Groothuis. Hepatobiliary secretion of organic compounds: molecular mechanisms of membrane transport. Biochim Biophys Acta 1241: 215-268, 1995.
148. NL Simons, J Hunter, MA Jepson. Renal secretion of xenobiotics mediated by Pglycoprotein: importance to renal function in health and exploitation for targeted drug delivery to epithelial cysts in polycystic kidney disease. Adv Drug Deliv Rev 25: 243-256, 1997.
149. A Tsuji, I Tarnai. Blood-brain barrier function of P-glycoprotein. Adv Drug Deliv Rev 25: 285-298, 1997.
150. J Hunter, BH Hirst. Intestinalsecretion of drugs. The role of P-glycoprotein and related drug efflux sstems in limiting oral drug absorption. Adv Drug Deliv Rev 25: 129-157, 1997.
151. WM Pardridge, PL Golden, YS Kang, U Bickel. Brain microvascular and astrocyte localization of P-glycoprotein. J Neurochem 68: 1278-1285, 1997.
152. WT Bellamy. P-glycoproteins and multidrug resistance. Ann Rev Pharmacol Toxicol 36: 161-183, 1996.
153. MM Gottesman, I Pastan. Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann Rev Biochem 62: 385-427, 1993.
154. MM Gottesman, CA Hrycyna, PV Schoenlein, UA Germann, I Pastan. Genetic analysis of the multidrug transporter. Ann Rev Genet 29: 607-649, 1995.
155. AR Safa multidrug resistance. In: RL Schilsky, GA Milano, MJ Ratain, et al. Principles of Antineoplasmic Drug Development and Pharmacology. New York: Marcel Dekker, 1996, pp 457-786.
156. H Kusuhara, H Suzuki, Y Sugiyama. The role of P-glycoprotein and canalicular multispecific organic anion transporter in the hepatobiliary excretion of drugs. J Pharm Sci 87: 1025-1040, 1998.
157. JJ Smit, AH Schinkel, RPJ Oude Elferink, AK Groen, E Wagenaar, L van Deemter, CAAM Mol, R Ottenhoff, NM van der Lugt, MA van Roon, MA van der Valk, GJ Offerhaus, AJM Berns, P Borst. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 75: 451-462, 1993.
158. S Ruetz, P Gros. Phosphatidylcholine translocase: a physiological role for the mdr2 gene. Cell 77: 1071-1081, 1994.
159. D de Graaf, RC Sharma, EB Mechetner, RT Schimke, IB Roninson. P-Glycoprotein confers methotrexate resistance in 3T6 cells with deficient carrier-mediated methotrexate uptake. Proc Natl Acad Sci USA 93: 1238-1242, 1996.
160. MD Norris, D De Graaf, M Haber, M Kavallaris, J Madafiglio, J Gilbert, E Kwan, BW Stewart, EB Mechetner, AV Gudkov, IB Roninson. Involvement of MDRI p- glycoprotein in multifactorial resistance to methotrexate. Int Natl Cancer 65: 613-619, 1996.
161. XY Chu, Y Kato, Y Sugiyama. Possible involvement of P-glycoprotein in biliary excretion of CPT-II in rats. Drug Metab Dispos 27: 440-441, 1999.
162. L Huang, T Hoffman, M Vore. Adenosine triphosphate-dependent transport of estradiol-17-beta(beta-D-glucuronide) in membrane vesicles by MDRI expressed in insect cells. Hepatology 28: 1371-1377, 1998.
163. AH Schinkel, JJ Smit, O van Tellingen, JH Beijnen, E Wagenaar, L van Deemter, CAAM Mol, MA van der Valk, EC Robanus-Maandag, HP te Riele, AJM Berns, P Borst. Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77: 491-502, 1994.
164. JW Smit, AH Schinkel, M Muller, B Weert, DKF Meijer. Contribution of the murine mdrl a P-glycoprotein to hepatobiliary and intestinal elimination of cationic drugs as measured in mice with an mdrla gene disruption. Hepatology 27: 1056-1063, 1998.
165. U Mayer, E Wagenaar, JH Beijnen, JW Smit, DK Meijer, J van Asperen, P Borst, AH Schinkel. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr la P-glycoprotein. Br J Pharmacol 119: 1038-1044, 1996.
166. A Sparreboom, J van Asperen, U Mayer, AH Schinkel, JW Smit, DK Meijer, P Borst, WJ Nooijen, JH Beijnen, O van Tellingen. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94: 2031-2035, 1997.
167. M Achira, H Suzuki, K Ito, Y Sugiyama. Comparative studies to determine the selective inhibitors for P-glycoprotein and cytochrome P450 3A4. AAPS Pharm Sci I, 1999. (available from http://www.pharmsci.org/journal)
168. H Kusuhara, H Suzuki, T Terasaki, A Kakee, M Lemaire, Y Sugiyama P-glycoprotein mediates the efflux of quinidine across the blood-brain barrier. J Pharmacol Exp Ther 283: 574-580, 1997.
169. AH Schinkel, E Wagenaar, CAAM Mol, L van Deemter. P-Glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97: 2517-2524, 1996.
170. AH Schinkel, E Wagenaar, L van Deemter, CAAM Mol, P Borst. Absence of the mdrIa P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 96: 1698-1705, 1995.
171. EC de Lange, G de Bock, AH Schinkel, AG de Boer, DD Breimer. BBB transport and P-glycoprotein functionality using MDRIA (- /-) and wild-type mice. Total brain versus microdialysis concentration profiles of rhodamine-123. Pharm Res 15: 1657-1665, 1998.
172. SP Cole, G Bhardwaj, JH Gerlach, JE Mackie, CE Grant, KC Almquist, AJ Stewart, EU Kurz, AM Duncan, RG Deeley. Overexpression of a transporter gene in a multidrug- resistant human lung cancer cell line. Science 258: 1650-1654, 1992.
173. SPC Cole, KE Sparks, K Fraser, DW Loe, CE Grant, GM Wilson, RG Deeley. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 54: 5902-5910, 1994.
174. BD Stride, CE Grant, DW Loe, DR Hipfner, SPC Cole, RG Deeley. Pharmacological characterization of the murine and human orthologs of multidrug-resistance protein in transfected human embryonic kidney cells. Mol Pharmacol 52: 344-353, 1997.
175. GJ Zaman, CH Versantvoort, JJ Smit, EW Eijdems, M de Haas, AJ Smith, HJ Broxterman, NH Mulder, EG de Vries, F Baas, P Borst. Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res 53: 1747-1750, 1993.
176. S Ruetz, M Brault, C Kast, C Hemenway, J Heitman, CE Grant, SP Cole, RG Deeley, P Gros. Functional expression of the multidrug resistance-associated protein in the yeast Saccharomyces cerevisiae. J Biol Chem 271: 4154-4160, 1996.
177. DW Loe, RG Deeley, SPC Cole. Biology of the multidrug resistance-associated protein, MRP. Eur J Cancer 32A: 945-957, 1996.
178. G Jedlitschky, I Leier, U Buchholz, K Bamouin, G Kurz, D Keppler. Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res 56: 988-994, 1996.
179. GJ Zaman, J Lankelma, D van Tellingen, J Beijnen, H Dekker, C Paulusma, RPJ Dude Elferink, F Baas, P Borst. Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. Proc Natl Acad Sci USA 92: 7690-7694, 1995.
180. CH Versantvoort, HJ Broxterman, T Bagrij, RJ Scheper, PR Twentyman. Regulation by glutathione of drug transport in multidrug-resistant human lung tumor cell lines overexpressing multidrug resistance-associated protein. Br J Cancer 72: 82-89, 1995.
181. DW Loe, KC Almquist, RG Deeley, SP Cole. Multidrug resistance protein (MRP)mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport. J Biol Chem 271: 9675-9682, 1996.
182. D Lautier, Y Canitrot, RG Deeley, SPC Cole. Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. Biochem Pharmacol 52: 967-977, 1996.
183. SP Cole, RG Deeley. Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP. Bioessays 20: 931-940, 1998.
184. RG Deeley, SP Cole. Function, evolution and structure of multidrug resistance protein (MRP). Semin Cancer Biol 8: 193-204, 1997.
185. REvers, GJ Zaman, L van Deemter, H Jansen, J Calafat, LC Domen, RPJ Dude Elferink, P Borst, AH Schinkel. Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. J Clin Invest 97: 1211-1218, 1996.
186. J Wijnholds, EC de Lange, GL Scheffer, OJ van Den Berg, CA Mol, M van Der Valk, AH Schinkel, RJ Scheper, DD Breimer, P Borst. Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. J Clin Invest 105: 279-285, 2000.
187. J Nishino, H Suzuki, D Sugiyama, T Kitazawa, K Ito, M Hanano, Y Sugiyama. Transepithelial transport of organic anions across the choroid plexus: possible involvement of organic anion transporter and multidrug resistance-associated protein. J Pharmacol Exp Ther 290: 289-294, 1999.
188. VV Rao, JL Dahlheimer, ME Bardgett, AZ Snyder, RA Finch, AC Sartorelli, D Piwnica-Worms. Choroid plexus epithelial expression ofMDR1 P-glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc Natl Acad Sci USA 96: 3900-3905, 1999.
189. N Strazielle. JF Ghersi-Egea. Demonstration of a coupled metabolism-efflux process at the choroid plexus as a mechanism of brain protection toward xenobiotics. J Neurosci 19: 6275-6289. 1999.
190. T Mikami, T Nozaki, O Tagaya. S Hosokawa, T Nakura, H Hori, S Kondou. Cong Anom 26: 250-251. 1986.
191. B Stieger, PJ Meier. Bile acid and xenobiotic transporters in liver. Curr Opin Cell Biol 10: 462-467, 1998.
192. H Suzuki, Y Sugiyama. Excretion of GSSG and glutathione conjugates mediated by MRPI and cMOAT/MRP2. Semin Liver Dis 18: 359-376. 1998.
193. J Konig, AT Nies, Y Cui, I Leier, D Keppler. Conjugate export pumps of the multidrug resistance protein (MRP) family: localization. substrate specificity. and MRP2-mediated drug resistance. Biochim Biophys Acta 1461: 377-394, 1999.
194. P Borst, R Evers, M Kool, J Wijnholds. The multidrug resistance protein family. Biochim Biophys Acta 1461: 347-357. 1999.
195. M Kuwano, S Toh, T Uchiumi, H Takano. K Kohno. M Wada. Multidrug resistance- associated protein subfamily transporters and drug resistance. Anticancer Drug Des 14: 123-131, 1999.
196. CC Paulusma, PJ Bosma, OJ Zaman. CT Bakker, MOtter. GL Scheffer. RJ Scheper. P Borst. RP Oude Elferink. Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science 271: 1126-1128, 1996.
197. K Ito. H Suzuki, T Hirohashi, K Kume, T Shimizu. Y Sugiyama. Molecular cloning of canalicular multispecific organic anion transporter defective in EHBR. Am J Physiol 272: 016-22, 1997.
198. M Buchler, J Konig, M Brom, J Kartenbeck, H Spring, T Horie, D Keppler. cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp. reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats. J Biol Chem 271: 15091-15098, 1996.
199. J Kartenbeck, U Leuschner, R Mayer, D Keppler. Absence of the canalicular isoform of the MRP gene-encoded conjugate export pump from the hepatocytes in Dubin-Johnson syndrome. Hepatol 23: 1061-1066, 1996.
200. MH de Vries, FA Redegeld, AS Koster, J Noordhoek, JG de Haan, RP Oude Elferink, PL Jansen. Hepatic, intestinal and renal transport of I-naphthol-beta-D-glucuronide in mutant rats with hereditary-conjugated hyperbilirubinemia. NaunynSchmiedebergs Arch Pharmacol 340: 588-592, 1989.
201. Y Gotoh, H Suzuki, S Kinoshita, T Hirohashi, Y Kato, Y Sugiyama. Involvement of an organic anion transporter (canalicular multispecific organic anion transporterl multidrug resistance-associated protein 2) in gastrointestinal secretion of glutathione conjugates in rats. J Pharmacol Exp Ther 292: 433-439, 2000.
202. T Hirohashi, H Suzuki, XY Chu, I Tarnai, A Tsuji, Y Sugiyama. Function and expression of multidrug resistance-associated protein family in human colon adenocarcinoma cells (Caco-2). J Pharmacol Exp Ther 292: 265-270, 2000.
203. K Taniguchi, M Wada, K Kohno, T Nakamura, T Kawabe, M Kawakami, K Kagotani. K Okumura, S Akiyama. M Kuwano. A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res 56: 4124-4129, 1996.
204. K Koike, T Kawabe, T Tanaka, S Toh, T Uchiumi, M Wada, S Akiyama, MOno, M Kuwano. A canalicular multispecific organic anion transporter (cMOAT) antisense eDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res 57: 5475-5479, 1997.
205. K Niinuma, Y Kato, H Suzuki, CA Tyson, V Weizer, JE Dabbs, R Froehlich, CE Green, Y Sugiyama. Primary active transport of organic anions on bile canalicular membrane in humans. Am J Physiol 276: GI153-1164, 1999.
206. Y Kiuchi, H Suzuki, T Hirohashi, CA Tyson, Y Sugiyama. cDNA cloning and inducible expression of human multidrug resistance associated protein 3 (MRP3). FEBS Lett 433: 149-152, 1998.
207. T Uchiumi, E Hinoshita, S Haga, T Nakamura, T Tanaka, S Toh, M Furukawa, T Kawabe, M Wada, K Kagotani, K Okumura, K Kohno, S Akiyama, M Kuwano. Isolation of a novel human canalicular multispecific organic anion transporter, cMOAT2/MRP3, and its expression in cisplatin-resistant cancer cells with decreased ATP-dependent drug transport. Biochem Biophys Res Commun 252: 103-110, 1998.
208. T Hirohashi, H Suzuki, Y Sugiyama. Characterization of the transport properties of cloned rat multidrug resistance-associated protein 3 (MRP3). J Biol Chem 274: 15181-15185, 1999.
209. DF Ortiz, S Li, R Iyer, X Zhang, P Novikoff, JM Arias. MRP3, a new ATP-binding cassette protein localized to the canalicular domain of the hepatocyte. Am J Physiol 276: G1493-1500, 1999.
210. J Konig, DRost, Y Cui, D Keppler. Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane. Hepatology 29: 1156-1163, 1999.
211. T Hirohashi, H Suzuki, H Takikawa, Y Sugiyama. ATP-dependent transport of bile salts by rat multidrug resistance-associated protein 3 (Mrp3). J Biol Chem 275: 2905-2910, 2000.
212. T Tsuruo, A Tomida. Multidrug resistance. Anti-Cancer Drugs 6: 213-218, 1995.
213. WT Beck In: RF Ozols, ed. Molecular and Clinical Advances in Anticancer Drug Resistance. Boston: Kluwer, 1991, pp 151-170.
214. JM Ford, WN Hail. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42: 155-199, 1990.
215. JM Ford. Modulators of multidrug resistance. Preclinical studies. Hematol Oncol Clin North America 9: 337-361, 1995.
216. MM Gottesman, GH Mickisch, I Pastan. In vivo models of P-glycoprotein-mediated multidrug resistance. Cancer Treat Res 73: 107-128, 1994.
217. RP Keller, HJ Altermatt, P Donatsch, H Zihlmann, JA Laissue, PC Hiestand. Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity. Int Natl Cancer 51 : 433-438, 1992.
218. S Desrayaud, P Guntz, JM Scherrmann, M Lemaire. Effect of the P-glycoprotein inhibitor, SDZ PSC 833, on the blood and brain pharmacokinetics of colchicine. Life Sci 61: 153-163, 1997.
219. A Sakata, J Tarnai, K Kawazu, Y Deguchi, T Ohnishi, A Saheki, A Tsuji. In vivo evidence for ATP-dependent and P-glycoprotein-mediated transport of cyclosporin A at the blood-brain barrier. Biochem Pharamacol 48: 1989-1992, 1994.
220. Q Wang, H Yang, OW Miller, WF Elmquist. Effect of the P-glycoprotein inhibitor, cyclosporin A, on the distribution of rhodamine-123 to the brain: an in vivo microdialysis study in freely moving rats. Biochem Biophys Res Commun 211: 719-726, 1995.
221. Q Wang, H Yang, WF Elmquist. The effect of LY-335979 on the distribution kinetics of quinidine to the brain: an in vivo microdialysis study in freely moving rats. Pharm Res 13: S-456, 1996.
222. A Hedman, B Angelin, A Arvidsson, R Oahlqvist, B Nilsson. Interactions in the renal and biliary elimination of digoxin: stereoselective difference between quinine and quinidine. Clin Pharmacol Ther 47: 20-26, 1990.
223. A Hedman, B Angelin, A Arvidsson, O Beck, R Dahlqvist, B Nilsson, M Olsson, K Schenck-Gustafsson. Oigoxin-verapamil interaction: reduction of biliary but not renal digoxin clearance in humans. Clin Pharmacol Ther 49: 256-262, 1991.
224. J Kuhlmann. Effects of verapamil, diltiazem, and nifedipine on plasma levels and renal excretions of digitoxin. Clin Pharmacol Ther 38: 667-673, 1985.
225. Polinga, M Merema, IH Hof, MJ Slooff, JH Proost, DK Meijer, GM Groothuis. Characterization of the uptake of rocuronium and digoxin in human hepatocytes: carrier specificity and comparison with in vivo data. J Pharmacol Exp Ther 285: 506-510, 1998.
226. A Hedman, OK Meijer. Stereoselective inhibition by the diasteromers quinidine and quinine of uptake of cardiac glycosides into isolated rat hepatocytes. J Pharm Sci 87: 457-461, 1998.
227. R Hori, N Okamura, TAiba, Y Tanigawara. Role of P-glycoprotein in renal tubular secretion of digoxin in the isolated perfused rat kidney. J Pharmacol Exp Ther 266: 1620-1625, 1993.
228. MF Fromm, RB Kim, CM Stein, GR Wilkinson, DM Roden. Inhibition of P-glycoprotein- mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 99: 552-557, 1999.
229. Y Emi, D Tsunashima, K Ogawara, K Higaki, T Kimura. Role of P-glycoprotein as a secretory mechanism in quinidine absorption from rat small intestine. J Pharm Sci 87: 295-299, 1998.
230. HH Kupferschmidt, KE Fattinger, HR Ha, F Follath, S Krahenbuhl. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br J Clin Pharmacol 45: 355-359, 1998.
231. A Hsu, GR Granneman, G Cao, L Carothers, T el-Shourbagy, P Baroldi, K Erdman, F Brown, E Sun, JM Leonard. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther 63: 453-464, 1998.
232. ME Fitzsimmons, JM Collins. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism. Drug Metab Dispos 25: 256-266, 1997.
233. VA Eagling, OJ Back, MG Barry. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 44: 190-194, 1997.
234. J Alsenz, H Steffen, R Alex., Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers. Pharm Res 15: 423-428, 1998.
235. W Muck, I Mai, L Fritsche, K Ochmann, G Rohde, S Unger, A Johne, S Bauer, K Budde, I Roots, HH Neumayer, J Kuhlmann. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Clin Pharmacol Ther 65: 251-261, 1999.
236. W Much, W Ritter, K Ochmann, S Unger, G Ahr, W Wingender, J Kuhlmann. Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin. Int J Clin Pharmacol Ther 35: 255-260, 1997.
237. M Boberg, R Angerbauer, P Fey, WK Kanhai, W Karl, A Kern, J Ploschke, M Radtke. Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P450 isozymes involved. Drug Metab Dispos 25: 321-331, 1997.
238. W Muck, K Ochmann, G Rohde, S Unger, J Kuhlmann. Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin. Eur J Clin Pharmacol 53: 469-473, 1998.
239. JH Pincus, K Barry. Protein distribution diet restores motor function in patients with dopa-resistant “off” period. Neurology 38: 481-483, 1988.
240. KL Audus, RT Borchardt. Characterization of the large neutral amino acid transport system of bovine brain microvessel endothelial cell monolayers. J Neurochem 47: 484-488, 1986.
241. NH Greig, S Momma, DJ Sweeney, QR Smith, SI Rapoport. Facilitated transport of melphalan at the rat blood-brain barrier by the large neutral amino acid carrier system. Cancer Res 47: 1571-1576, 1987.
242. SH Blondheim. Effect of probenecid on excretion of bromosulphthalein. J Clin Invest 7: 529-532, 1955.
243. AG Gilman, TW Rall, AS Nies, P Taylor. In: Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 8th ed. New York: Pergamon press, 1990.
244. RS Bourke, G Chheda, A Bremer, O Watanabe, DB Tower. Inhibition of renal tubular transport of methotrexate by probenecid. Cancer Res 35: 110-116, 1975.
245. WM Williams, TS Chen, KC Huang. Effect of penicillin on the renal tubular secretion of methotrexate in the monkey. Cancer Res 44: 1913-1917, 1984.
246. DW Nierenerg. Drug inhibition of penicillin tubular secretion: concordance between in vitro and clinical findings. J Pharmacol Exp Ther 240: 712-716, 1987.
247. SP Boom, I Meyer, AC Wouterse, FG Russel. A physiologically based kidney model for the renal clearance of ranitidine and the interaction with cimetidine and probenecid in the dog. Biopharm Drug Dispos 19: 199-208, 1998.
248. U Jaehde, F Sorgel, A Reiter, G Sigl, KG Naber, W Schunack. Effect of probenecid on the distribution and elimination of ciprofloxacin in humans. Clin Phamacol Ther 58: 532-541, 1995.
249. TB Vree, M Van den Biggelaar-martea, CPWGM Verwey-van Wissen. Probenecid inhibits the renal clearance of frusemide and its acyglucuronide. Br J Clin Pharmac 39: 692-695, 1995.
250. TM Garrigues, U Martin, IE Peris-Ribera, LF Prescott. Dose-dependent absorption and elimination of cefadroxil in man. Eur J Clin Phannacol 41: 179-183, 1991.
251. JPF Bai, GL Amidon. Structural specificity of mucosal-cell transport and metabo- lism of peptide drugs: implication for oral peptide drug delivery. Pharm Res 9: 969-978, 1992.
252. LK Christensen, JM Hansen, M Kristensen. Sulfaphenazole-induced hypoglycaemic attacks in tolbutamide treated diabetics. Lancet 2: 1298-1301, 1963.
253. M Rowland, SB Martin. Kinetics of drug-drug interactions. J Pharmacokinet Biopharm 1: 553-567, 1973.
254. J Shibasaki, R Konishi, K Yamazaki. Tolbutamide-sulphaphenazole interaction in rabbits. J Pharmacokinet Biopharm 5: 277-290, 1977.
255. O Sugita, Y Sawada, Y Sugiyama, T Iga, M Hanano. Physiological based pharmacokinetics of drug-drug interaction: a study of tolbutamide-sulfonamide interaction in rats. J Pharmcokin Biopharm 10: 297-316, 1982.
256. H Takanaga, H Murakami, N Koyabu, H Matsuo, M Naito, T Tsuruo, Y Sawada. Efflux transport of tolubutamide across the blood-brain barrier. J Pharm Pharmcol 50: 1027-1033, 1998.
257. K Okudaira, Y Sawada, Y Sugiyama, T Iga, M Hanano. Effects of basic drugs on the hepatic transport of cardiac glycosides in rats. Biochem Pharmacol 37: 2949-2955, 1988.
258. PW Wigler, KL Lyon, K Patterson, AJ Loggia, H Diazarauzo, MS Reddy, JM Cook. Epoxide metabolite of quinine and inhibition of the multidrug resistance pump in human leukemic Iymphoblasts. Mol Pharmacol 46: 563-567, 1994.
259. S Song, H Suzuki, R Kawai, C Tanaka, I Akasaka, Y Sugiyama. Dose-dependent effects of PSC 833 on its tissue distribution and on the biliary excretion of endogenous substrates in rats. Drug Metab Dispos 26: 1128-1133, 1998.
260. N Simon, E Dailly, S Combes, E Malaurie, M Lemaire, JP Tillement, S Urien. Role of lipoprotein in the plasma binding of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin. Br J Clin Pharmacol 45: 173-175, 1998.
261. D Boesch, K Muller, A Pourtier-Manzanedo, FLoor. Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative. Exp Cell Res 196: 26-32, 1991.
262. M Bohme, G Jedlitschky, I Leier, M Buchler, D Keppler. ATP-dependent export pumps and their inhibition by cyclosporins. Adv Enzyme Regulation 34: 371-380, 1994.
263. S Masuda, H Saito, K Inui. Interactions of nonsteroidal anti-inflammatory drugs with rat renal organic anion transporter, OAT-KI. J Pharmacol Exp Ther 283: 1039-1042, 1997.
264. BM Emanuelsson, B Beermann, LK Paalzow. Non-linear elimination and protein binding of probenecid. Eur J Clin Pharmacol 32: 395-401, 1989.
265. N Kanai, R Lu, Y Bao, AW Wolkoff, VL Schuster. Transient expression of oatp organic anion transporter in mammalian cells: identification of candidate substrates. Am J Physiol 270: F319-325, 1996.
266. T Kitamura, P Jansen, C Hardenbrook, Y Kamimoto, Z Gatmaitan, JM Arias. Defective ATP-dependent bile canalicular transport of organic anions in mutant (TR-) rats with conjugated hyperbilirubinemia. Proc Natl Acad Sci USA 87: 3557-3561, 1990.
267. PJ Sinko, GL Amidon. Characterization ofthe oral absorption of beta-Iactam antibi- otics. I. Cephalosporins: detennination of intrinsic membrane absorption parameters in the rat intestine in situ. Pharm Res 5: 645-650, 1988.
268. AE Busch, S Quester, JC Ulzheimer, V Gorboulev, A Akhoundova, S Waldegger, F Lang, HKoepsell. Monoamine neurotransmitter transport mediated by the polyspecific cation transporter rOCTI. FEBS Lett 395: 153-156, 1996.
269. T Breidert, F Spitzenberger, D Grundemann, E Schomig. Catecholamine transport by the organic cation transporter type 1 (OCTI). Br J Phannacol 125: 218-224, 1998.
270. L Zhang, ME Schaner, KM Giacomini. Functional characterization of an organic cation transporter (hOCTI) in a transiently transfected human cell line (HeLa). J Phannacol Exp Ther 286: 354-361, 1998.
271. L Zhang, MJ Dresser, AT Gray, SC Yost, S Terashita, KM Giacomini. Cloning and functional expression of a human liver organic canion transporter. Mol Pharmacol 51: 913-921, 1997.
272. M Okuda, H Saito, Y Urakami, M Takano, K Inu L eDNA cloning and functional expression of a novel rat kidney organic cation transporter, OCTI. Biochem Biophys Res Commun 224: 500-507, 1996.
273. D Grundemann, S Koster, N Kiefer, T Breidert, M Engelhardt, F Spitzenberger, N Obermuller, E Schomig. Transport of monoamine transmitters by the organic cation transporter type 2, OCT2. J Biol Chem 273: 30915-30920, 1998.
274. AE Busch, U Karbach, D Miska, V Gorboulev, A Akhoundova, C Volk, P Arndt, JC Ulzheimer, MS Sonders, C Baumann, S Waldegger, F Lang, H Koepsell. Human neurons express the polyspecific cation transporter hOCTI, which translocates monoamine neurotransmitters, amantadine, and memantine. Mol Pharmacol 54: 342-352, 1998.
275. Y Zhu, MC Jong, KA Frazer, E Gong, RM Krauss, JF Cheng, D Boffelli, EM Rubin. Genomic interval engineering of mice identifies a novel modulator of triglyceride production. Proc Natl Acad Sci USA 97: 1137-1142, 2000.
276. T Sekine, H Kusuhara, N Utsunomiya-Tate, M Tsuda, Y Sugiyama, Y Kanai, H Endou. Molecular cloning and characterization of high-affinity camitine transporter from rat intestine. Biochem Biophys Res Commun 251: 586-591, 1998.
277. U Eckhardt, IA Horz, E Petzinger, W Stuber, M Reers, G Dickneite, H Daniel, M Wagener, B Hagenbuch, B Stieger, PJ Meier. The peptide-based thrombin inhibitor CRC 220 is a new substrate of the basolateral rat liver organic anion-transporting polypeptide. Hepatology 24: 380-384, 1996.
278. U Eckhardt, A Schroeder, B Stieger, M Hochli, L Landmann, R Tynes, PI Meier, B Hagenbuch. Polyspecific substrate uptake by the hepatic organic anion transporter Oatp1 in stably transfected CHO cells. Am I Physiol 276: G1037-1042, 1999.
279. KS Pang, PJ Wang, AY Chung, AW Wolkoff. The modified dipeptide, enalapril, an angiotensin-converting enzyme inhibitor, is transported by the rat liver organic anion transport protein. Hepatology 28: 1341-1346, 1998.
280. M Kontaxi, U Echkardt, B Hagenbuch, B Stieger, PJ Meier, E Petzinger. Uptake of the mycotoxin ochratoxin A in liver cells occurs via the cloned organic anion transporting polypeptide. I Pharmacol Exp Ther 279: 1507-1513, 1996.
281. H Ishizuka, K Konno, H Naganuma, K Nishimura, H Kouzuki, H Suzuki, B Stieger, PJ Meier, Y Sugiyama. Transport of temocaprilat into rat hepatocytes: role of organic anion transporting polypeptide. J Pharmacol Exp Ther 287: 37-42, 1998.
282. T Tokui, D Nakai, R Nakagomi, H Yawo, T Abe, Y Sugiyama. Pravastatin, an HMG-CoA reductase inhibitor, is transported by rat organic anion transporting polypeptide, oatp2. Pharm Res 16: 904-908, 1999.
283. T Cihlar, DC Lin, JB Pritchard, MD Fuller, DB Mendel, DH Sweet. The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Mol Pharmacol 56: 570-580, 1999.
284. M Hosoyamada, T Sekine, Y Kanai, H Endou. Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. Am J Physiol 276: F122-128, 1999.
285. R Lu, BS Chan, VL Schuster. Cloning of the human kidney PAH transporter: narrow substrate specificity and regulation by protein kinase C. Am J Physiol 276: F295-303, 1999.
286. H Saito, M Okuda, T Terada, S Sasaki, K Inui. Cloning and characterization of a rat H+/peptide cotransporter mediating absorption of beta-lactam antibiotics in the intestine and kidney. J Pharmacol Exp Ther 275: 1631-1637, 1995.
287. A Tsuji, I Tarnai. Carrier-mediated intestinal transport of drugs. Pharm Res 13: 963-977, 1996.
288. M Boll, D Markovich, WM Weber, H Korte, H Daniel, H Murer. Expression cloning of a cDNA from rabbit small intestine related to proton-coupled transport of peptides, beta-lactam antibiotics and ACE-inhibitors. Pflugers Arch 429: 146-149, 1994.
289. ME Ganapathy, M Brandsch, PD Prasad, V Ganapathy, FH Leibach. Differential recognition of beta-lactam antibiotics by intestinal and renal peptide transporters, PEPT I and PEPT2. J Biol Chem 270: 25672-25677, 1995.
290. ME Ganapathy, PD Prasad, B Mackenzie, V Ganapathy, PH Leibach. Interaction of anionic cephalosporins with the intestinal and renal peptide transporters PEPT 1 and PEPT 2. Biochim Biophys Acta 1324: 296-308, 1997.
291. R Liang, YI Fei, PD Prasad, S Ramamoorthy, H Han, TL Yang-Feng, MA Hediger, V Ganapathy, FH Leibach. Human intestinal H+/peptide cotransporter. Cloning, functional expression, and chromosomal localization. J Biol Chem 270: 6456-6463, 1995.
292. WLiu, R Liang, S Ramamoorthy, YJ Fei, ME Ganapathy, MA Hediger, V Ganapathy, FH Leibach. Molecular cloning of PEPT 2, a new member of the W/peptide cotransporter family, from human kidney. Biochim Biophys Acta 1235: 461-466, 1995.
293. NH Hendrikse, AH Schinkel, EG de Vries, E Fluks, WT Van der Graaf, AT Willemsen, W Vaalburg, EJ Franssen. Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. Br J Pharmacol 124: 1413-1418, 1998.
294. S Desrayaud, EC De Lange, M Lemaire, A Bruelisauer, AG De Boer, DD Breimer. Effect of the Mdrla P-glycoprotein gene disruption on the tissue distribution of SDZ PSC 833, a multidrug resistance-reversing agent, in mice. J Pharmacol Exp Ther 285: 438-443, 1998.
295. K Yokogawa, M Takahashi, I Tarnai, H Konishi, M Nomura, S Moritani, K Miya- moto, A Tsuji. P-glycoprotein-dependent disposition kinetics of tacrolimus: studies in mdrla knockout mice. Pharm Res 16: 1213-1218, 1999.
296. RB Kim, MF Fromm, C Wandel, B Leake, AJ Wood, DM Roden, GR Wilkinson. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV1 protease inhibitors. J Clin Invest 101: 289-294, 1998.
297. J van Asperen, O van Tellingen, F Tijssen, AH Schinkel, JH Beijnen. Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdrla P-glycoprotein. Br J Cancer 79: 108-113, 1999.
298. JW Jonker, E Wagenaar, L van Deemter, R Gottschlich, HM Bender, J Dasenbrock, AH Schinkel. Role of blood-brain barrier P-glycoprotein in limiting brain accumulation and sedative side effects of asimadoline, a peripherally acting analgaesic drug. Br J Pharmacol 127: 43-50, 1999.
299. M Murata, I Tarnai, H Kato, O Nagata, A Tsuji. Efflux transport of a new quinolone antibacterial agent, HSR-903, across the blood-brain barrier. J Pharmacol Exp Ther 290: 51-57, 1999.
300. JW Polli, JL Jarrett, SD Studenberg, IE Humphreys, SW Dennis, KR Brouwer, JL Woolley. Role of P-glycoprotein on the CNS disposition of amprenavir (141 W94), an HIV protease inhibitor. Pharm Res 16: 1206-1212, 1999.
301. T Kawabe, ZS Chen, M Wada, T Uchiumi, MOno, S Akiyama, M Kuwano. Enhanced transport of anticancer agents and leukotriene C4 by the human canalicular multispecific organic anion transporter (cMOAT/MRP2). FEBS Lett 456: 327-331, 1999.
302. T Kamisako, I Leier, Y Cui, J Konig, U Buchholz, J Hummel-Eisenbeiss, D Keppler. Transport of monoglucuronosyl and bisglucuronosyl bilirubin by recombinant human and rat multidrug resistance protein 2. Hepatology 30: 485-490, 1999.
303. CWN Chiang, LZ Benet. Dose-dependent kinetics of probenecid in rhesus monkeys- intravenous bolus studies. Pharmacology 23: 326-336, 1981.
304. MI Sheikh, J Maxild. Kinetics studies on the renal transport of probenecid in vitro. Biochim Biophys Acta 514: 356-361, 1978.
305. V Cattori, B Hagenbuch, N Hagenbuch, B Stieger, R Ha, KE Winterhalter, PJ Meier. Identification of organic anion transporting polypeptide 4 (Oatp4) as a major full-length isoform of the liver-specific transporter-l (r1st-l) in rat liver. FEBS Lett 474: 242-245, 2000.
306. Y Cui, J Konig, II Leier, U Buchholz, D Keppler. Hepatic uptake of bilirubin and its conjutates by the human organic anion-transporting polypeptide 2 (symbol SLC21A6). J Biol Chem 27: 27, 2000.
307. J Konig, Y Cui, AT Nies, D Keppler. Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J Biol Chem 275: 23161-23168, 2000.
308. GA Kullak-Ublick, MG Ismair, B Steiger, L Landmann, R Huber, F Pizzagalli, K Fattinger, PJ Meier, B Hagenbuch. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 120: 525-533, 2001.
309. SH Cha, T Sekine, J Fukushima, Y Kanai, Y Kobayashi, T Goya, H Endou. Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol 59: 1277-1286, 2001.